{"corpus_id":210978506,"paper_sha":"86b4018633d5c25bf1575a9cf09520869a994585","doi":"10.1016/S0140-6736(20)30068-4","arxiv_id":null,"pmid":32007141,"pmcid":"7043009","mag_id":3003249044,"dblp_id":null,"acl_id":null,"title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","year":2020,"publication_date":"2020-01-30","venue":"The Lancet","journal":{"name":"Lancet (London, England)","pages":"575 - 590","volume":"395"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Comparative Study","Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine","Economics"],"reference_count":63,"citation_count":642,"influential_citation_count":20,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Developing Countries","mj":false,"ui":"D003906"},{"d":"Early Detection of Cancer","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D055088"},{"d":"Feasibility Studies","mj":false,"ui":"D005240"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Incidence","mj":false,"ui":"D015994"},{"d":"Income","mj":false,"ui":"D007182"},{"d":"Mass Screening","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D008403"},{"d":"Models, Biological","mj":false,"ui":"D008954"},{"d":"Papillomavirus Infections","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"},{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D030361"},{"d":"Papillomavirus Vaccines","mj":true,"ui":"D053918"},{"d":"Uterine Cervical Neoplasms","mj":false,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"epidemiology","mj":false,"ui":"Q000453"},{"q":"prevention & control","mj":true,"ui":"Q000517"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D002583"},{"d":"Vaccination","mj":false,"ui":"D014611"}],"chemicals":[{"n":"Papillomavirus Vaccines","ui":"D053918","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.thelancet.com/article/S0140673620300684/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/86b4018633d5c25bf1575a9cf09520869a994585","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination. Methods The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions. Findings Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4–19·8) to 2·1 (2·0–2·6) cases per 100 000 women-years over the next century (89·4% [86·2–90·1] reduction), and to avert 61·0 million (60·5–63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6–1·6) cases per 100 000 women-years (96·7% [91·3–96·7] reduction) and averted an extra 12·1 million (9·5–13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58–65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89–100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37–99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71–100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11–31 years. Long-term vaccine protection was required for elimination. Interpretation Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden. Funding WHO, UNDP, UN Population Fund, UNICEF–WHO–World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec–Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.","claims":[{"public_id":"cl_7d038c2ca7bddad9f6682881544342e8","status":"active","text":"Adding twice-lifetime screening (HPV testing at ages 35 and 45, uptake increasing from 45% to 90%) to girls-only vaccination reduces incidence to 0.7 cases per 100,000 women-years (96.7% reduction) and averts an extra 12.1 million cases.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_7d038c2ca7bddad9f6682881544342e8"},{"public_id":"cl_1f4ab5a6085bb20c5a878b89a9463e17","status":"active","text":"Adding twice-lifetime screening enables 100% of LMICs to reach elimination for all three thresholds (≤4, ≤10, ≥85% reduction).","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_1f4ab5a6085bb20c5a878b89a9463e17"},{"public_id":"cl_e681dfdc699fd0890ca076dcf7aaa45b","status":"active","text":"Girls-only HPV vaccination (90% coverage, 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, 58) is predicted to reduce median age-standardised cervical cancer incidence in LMICs from 19.8 to 2.1 cases per 100,000 women-years over the next century (89.4% reduction) and avert 61.0 million cases.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_e681dfdc699fd0890ca076dcf7aaa45b"},{"public_id":"cl_1d762752390017dcd79e5a4e2f5cfeb3","status":"active","text":"Girls-only vaccination alone is predicted to achieve elimination (≤4 cases per 100,000 women-years) in 60% of LMICs, elimination (≤10 cases per 100,000 women-years) in 99% of LMICs, and elimination (≥85% reduction) in 87% of LMICs.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_1d762752390017dcd79e5a4e2f5cfeb3"},{"public_id":"cl_8a79395e037fe5ded6dd33baf2f13019","status":"active","text":"In regions where all countries achieve elimination with girls-only vaccination, elimination occurs between 2059 and 2102; adding twice-lifetime screening accelerates elimination by 11–31 years.","confidence":0.85,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_8a79395e037fe5ded6dd33baf2f13019"}],"concepts":[{"public_id":"co_00a641ec0f1bf61c4f1004dff848b41e","status":"active","name":"cases averted","description":"The number of cervical cancer cases prevented over the modelled century: 61.0 million with girls-only vaccination and an extra 12.1 million with added twice-lifetime screening.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_00a641ec0f1bf61c4f1004dff848b41e"},{"public_id":"co_345b7b87f357885b3b795a2e94eed94d","status":"active","name":"cervical cancer elimination timing","description":"The predicted year range (2059–2102) when elimination is achieved in regions where all countries reach elimination with girls-only vaccination, and the acceleration (11–31 years) from adding twice-lifetime screening.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_345b7b87f357885b3b795a2e94eed94d"},{"public_id":"co_479112d7d05dfaf47588dfdb380c3c07","status":"active","name":"long-term vaccine protection","description":"The assumption of 100% lifetime protection required for elimination in the modelled scenarios.","types":["assumption"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_479112d7d05dfaf47588dfdb380c3c07"},{"public_id":"co_4e07ba6ff32ca193f82df27f8fad02f5","status":"active","name":"girls-only HPV vaccination","description":"Vaccination of girls at age 9 years with catch-up to age 14, assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58.","types":["intervention"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_4e07ba6ff32ca193f82df27f8fad02f5"},{"public_id":"co_4fcc5ac9a8c59cc1eb6fd5c72c644339","status":"active","name":"low-income and lower-middle-income countries","description":"The 78 LMICs included in the modelling analysis.","types":["population"],"aliases":["LMICs"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_4fcc5ac9a8c59cc1eb6fd5c72c644339"},{"public_id":"co_7c5ccec45e6af86a34d14134cef1edf2","status":"active","name":"WHO Cervical Cancer Elimination Modelling Consortium","description":"The consortium consisting of three independent transmission-dynamic models used to project reductions in cervical cancer incidence.","types":["organization"],"aliases":["CCEMC"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_7c5ccec45e6af86a34d14134cef1edf2"},{"public_id":"co_7f0e87b022292eabc59fb7629e7c2eea","status":"active","name":"twice-lifetime screening","description":"Cervical screening involving HPV testing once or twice per lifetime at ages 35 and 45, with uptake increasing from 45% (2023) to 90% (2045 onwards).","types":["intervention"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_7f0e87b022292eabc59fb7629e7c2eea"},{"public_id":"co_8345a5d96f5a54c45b53170764eae621","status":"active","name":"median age-standardised cervical cancer incidence","description":"The median of model-predicted age-standardised cervical cancer incidence rates across LMICs, expressed as cases per 100,000 women-years.","types":["metric"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_8345a5d96f5a54c45b53170764eae621"},{"public_id":"co_8dfd530d6c48986e0b4e41c247d5c8eb","status":"active","name":"cervical cancer elimination thresholds","description":"The three thresholds examined: average age-standardised incidence ≤4 per 100,000 women-years, ≤10 per 100,000 women-years, and ≥85% reduction in incidence.","types":["criterion"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_8dfd530d6c48986e0b4e41c247d5c8eb"},{"public_id":"co_b5955a016db77c5db8c73a0f82479f86","status":"active","name":"HPV types 16, 18, 31, 33, 45, 52, 58","description":"The seven HPV types against which the modelled vaccination provides 100% lifetime protection.","types":["target"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_b5955a016db77c5db8c73a0f82479f86"}],"external_ids":{"DOI":"10.1016/S0140-6736(20)30068-4","ArXiv":null,"PubMed":32007141,"PubMedCentral":"7043009","MAG":3003249044,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.thelancet.com/article/S0140673620300684/pdf","landing_url":"https://www.semanticscholar.org/paper/86b4018633d5c25bf1575a9cf09520869a994585","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634320,"paper_uid":"12582931-493a-4d06-b216-dd2f7092aa27","canonical_identity":{"paper_id":634320,"paper_uid":"12582931-493a-4d06-b216-dd2f7092aa27","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/210978506"}